In gram-negative bacteria, the most common mechanism of resistance is the hydrolysis, or breaking apart, of the antibiotics by enzymes referred to as the beta-lactamases. There are two broad classes ...

including those that work in combination with beta-lactamase production. We are also studying permeability mechanisms of aminoglycoside resistance in E. coli and we are using genomic surveillance to ...

is one of the major mechanisms of antibiotic resistance. Plasmid borne genes encoding modifying enzymes such as beta-lactamases, that confer resistance to penicillins and related antibiotics, or, more ...

Beta-lactamase inhibitors are designed to overcome a key resistance mechanism that allows pathogens to protect themselves from beta-lactams, one of the most commonly-used antibiotic classes.

Recarbrio – which based on established antibiotic combination imipenem/cilastatin with Merck’s new beta-lactamase inhibitor ... to inhibit a key resistance mechanism that limits the ...

His main research interest is understanding the molecular basis of beta-lactamase-mediated antibiotic resistance ... research interests continue to revolve around the molecular mechanisms of ...

Most studies evaluating combinations of macrolides and beta-lactamase antibiotics or beta-lactamase agents used alone (eg, ampicillin) did not show benefit. A single study using metronidazole ...

Antibiotic resistance (ABR ... also determined that some of the potential inhibitors bound directly to the metallo-beta-lactamases, inactivating them – the ideal mechanism for inhibitors to progress ...

Emblaveo is the first monobactam/beta-lactamase inhibitor and antibiotic combination approved for this condition. The approval was based on results from the phase 3 REVISIT trial. The FDA has ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...